JAKARTA, 22 September 2022 - KALGen INNOLAB is a joint investment laboratory between PT Kalbe Farma Tbk and a Japanese company, which continues to innovate in providing the best services in the health sector, especially molecular genomic examination services to support more precise treatment. Molecular diagnostics, which analyze biological markers genomically or proteomically, provide crucial insights into an individual's body. The results of these tests can be used to determine lifestyle choices, assess disease risks, diagnose infectious diseases, and even aid in cancer treatment.
- Virgi Saputra, Senior Marketing Manager of PT Innolab Sains Internasional (KALGen INNOLAB) "Lifestyle, disease risk, and treatment will continue to develop in a personalized direction or depend on each individual's DNA. KALGen INNOLAB aims to contribute to the rapidly evolving field of personalized medicine in Indonesia." she said.
One prominent example of personalized medicine is the treatment of lung cancer. Instead of relying solely on chemotherapy, targeted therapy drugs and immunotherapy are now employed. Patients diagnosed with lung cancer will then carry out molecular diagnostic tests, such as the EGFR (epidermal growth factor receptor) mutation test using the RT-PCR method, ALK, and PD-L1 using the immunohistochemical method. These tests help identify the appropriate targeted therapy drugs, improving treatment effectiveness.
EGFR is one of the various types of gene mutations that examined quite often in lung cancer because the results affect the determination of targeted therapy drugs in the form of oral tablets. Apart from the EGFR mutation test, there are at least 12 other genes that are commonly found in lung cancer cases, namely EGFR, ALK, ROS1, KRAS, NRAS, BRAF, MET, RET, PIK3CA, MAP2K1, ERBB2, and TP53.
Recognizing the urgency with which lung cancer patients must treated, KALGen INNOLAB uses Next Generation Sequencing (NGS) technology to present a multigene panel test known as OncoPANEL-Lung. This molecular diagnostic test consists of 12 genes or biomarkers often detected in lung cancer, offering the benefit by accelerating the examination process, providing accurate and swift prognosis and therapeutic regimen selection.
Beyond diagnosing diseases, molecular diagnostics can also used as a risk assessment for awareness of cancer risk and wellness. An example of molecular diagnostics in cancer risk awareness is the BRCA 1-2 gene mutation test. BRCA 1-2 mutations have a lot to do with heredity. Positive results for BRCA 1-2 gene mutations can also indicate a higher risk profile for breast, prostate, ovarian, pancreatic, and prostate cancer than the general average population. Therefore routine medical check-up activities can be advised by doctors.
Furthermore, in today's society, as individuals become increasingly health-conscious, lifestyle patterns are becoming increasingly significant.
Molecular diagnostics also play an essential role in directing an optimal lifestyle choices based on the outcome of each individual's DNA test. Examples of wellness tests such as NutriGEN-ME can be checked only once in a lifetime with the result of a list of good foods to eat, exercise, and a tendency for metabolic diseases that can occur according to the results of an individual's DNA test.
Furthermore, as individuals become increasingly health-conscious, lifestyle patterns play a significant role. Molecular diagnostics aid in directing optimal lifestyle choices based on an individual's DNA test results. Wellness tests, like NutriGEN-ME, provide personalized recommendations on nutrition, exercise, and metabolic disease tendencies, empowering individuals to lead healthier lives.
It is hoped that tests conducted at KALGen INNOLAB will aid individuals and professionals in making accurate diagnoses and selecting the best therapy for their patients.
About KALGen INNOLAB
KALGen INNOLAB Clinical Laboratory under PT Innolab Sains Internasional is a joint venture company between PT Kalbe Farma Tbk and Toyota Tsusho Corporation (TTC) and 'Hoken Kagaku Kenkyujo (HKK)' in Japanese.
As the first foreign investment joint venture company in the field of Clinical Laboratory to obtain a license from the Indonesian Ministry of Health, KALGen Innolab is expected to contribute to the improvement of public health in general, particularly in relation to specialist examinations with Japanese standards which are widely known to have the best quality assurance.